November 10, 2009Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis BiologicOctober 31, 2009Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis COctober 23, 2009Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain CancerSeptember 24, 2009Medarex, Inc. Issues Notice of Change in Control to Holders of its Convertible NotesSeptember 15, 2009Bristol-Myers Squibb Company Announces Sale to Taisho Pharmaceutical Co Ltd., of Its OTC Assets in Asia Pacific (Excl. China & Japan) and Shares in PT Bristol-Myers Squibb Indonesia TbkJune 6, 2009Interim Analysis of Long-Term Data with ONGLYZA™ (saxagliptin) When Added to Metformin in People with Inadequately Controlled Type 2 Diabetes Presented at ADA Annual Scientific SessionsJune 6, 2009Dapagliflozin Study Demonstrated Improved Glycemic Control In Type 2 Diabetes Patients Treated With High Doses of Insulin and Common Oral Anti-Diabetic MedicinesMay 31, 2009Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg)April 24, 2009Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis CApril 6, 2009Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY® and Establishment of an Oncology Collaboration with OtsukaMarch 4, 2009Bristol-Myers Squibb Enters Global Collaboration with Nissan Chemical and Teijin Pharma on Novel Atrial Fibrillation CompoundJanuary 12, 2009Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C CompoundDecember 12, 2008Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Novel Cancer ProgramsAugust 19, 2008Bristol-Myers Squibb and PDL BioPharma Enter Global Alliance to Develop Novel Treatment for Multiple MyelomaMay 29, 2008Bristol-Myers Squibb to Acquire Kosan BiosciencesMay 13, 2008Bristol-Myers Squibb and KAI Pharmaceuticals Enter Global Alliance to Develop and Commercialize KAI-9803 for Cardiovascular DiseaseSeptember 24, 2007Bristol-Myers Squibb to Acquire Adnexus Therapeutics
|
|